Sunil Healthcare Not Classified as SEBI 'Large Corporate'

Sunil Healthcare has formally confirmed it does not meet the Securities and Exchange Board of India's (SEBI) criteria to be classified as a 'Large Corporate' (LC). This clarification follows financial reporting that places the company's outstanding borrowings at ₹19.08 crore as of March 31, 2026. Maintaining a CARE BB+ (Stable) credit rating for fiscal year 2025-26, Sunil Healthcare is thus exempt from SEBI's more stringent disclosure requirements for debt issuance mandated for identified LCs.

Why SEBI's 'Large Corporate' Rules Matter

SEBI introduced the 'Large Corporate' framework to encourage deeper engagement with the debt market and reduce companies' reliance on traditional bank financing. Identified LCs have specific obligations, including raising a portion of their incremental borrowings through debt securities. By not being classified as an LC, Sunil Healthcare avoids these compliance burdens and disclosure requirements, which can be complex and resource-intensive.

Background: Large Corporate Criteria

Under SEBI's current framework, an entity is typically classified as a 'Large Corporate' if it has outstanding long-term borrowings of at least ₹100 crore and a credit rating of 'AA' or higher. Sunil Healthcare's outstanding borrowing of ₹19.08 crore as of March 31, 2026, falls significantly below this threshold. While SEBI has considered proposals to raise this threshold, the company's current declaration confirms it does not meet the prevailing criteria.

Implications of Current Status

Sunil Healthcare is not required to comply with SEBI's mandatory disclosure norms for Large Corporates concerning debt issuance. The company is exempt from the obligation to raise a specific percentage of its incremental borrowings through debt securities. This simplifies its fundraising compliance landscape, allowing it to pursue debt financing (if any) without the additional LC-specific regulatory overlay.

Key Risks for Sunil Healthcare

CARE Ratings has highlighted a stretched liquidity position for Sunil Healthcare, citing significant outstanding receivables (over 180 days) and high utilization of working capital limits. The company faces declining revenues in FY25, limiting financial flexibility. Profitability margins have been a concern, with negative PAT recorded in FY24. The capsule manufacturing industry is highly competitive, subject to regulatory risks, and sensitive to raw material price volatility.

Peer Mention

UTL Industries Ltd. also declared it does not meet SEBI's 'Large Corporate' criteria as of March 31, 2026, indicating a similar exemption from specific debt disclosure requirements for FY 2025-2026.

Credit Rating Details

Credit Rating for FY 2025-26: CARE BB+ (Stable) by CARE Ratings Ltd.

What to Track Next

Future plans for debt issuance and how the company intends to finance its operations. Management's strategy to improve liquidity and reduce the high level of receivables. Efforts to reverse the declining trend in operations and improve profitability. Developments in the company's credit rating and its ability to access financing.